YOLFTbeta
Faeth Therapeutics, Inc.

Faeth Therapeutics, Inc.

FTH · NASDAQ · Healthcare / Biotechnology

10.03USD-0.62 (-5.82%)

Price History

Full chart

Market Stats

Previous Close10.65
Open10.51
Day Range9.67 – 10.63
52-Week Range7.45 – 42.14
Volume1.04M
Market Cap750.66M
P/E (TTM)0.00
Forward P/E0.00
EPS-55.92
Dividend Yield0.00%
Beta-0.28
50-Day Avg31.74
200-Day Avg23.41

About

Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-102 and SNS-103, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. The company was formerly known as Sensei Biotherapeutics, Inc. and changed its name to Faeth Therapeutics, Inc. in June 2026. The company was incorporated in 1999 and is headquartered in Rockville, Maryland.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Anand Parikh Esq., J.D.
  • Employees29
  • Headquarters1405 Research Boulevard, Rockville, MD, United States, 20850, USA
  • Websitehttps://www.faeththerapeutics.com

Leadership

  • Mr. Josiah Craver CPASenior VP of Finance, Principal Financial Officer & Principal Accounting Officer
  • Mr. Christopher W. Gerry J.D.General Counsel & Secretary · b. 1980
  • Mr. Anand Parikh Esq., J.D.CEO, President & Chair · b. 1986
  • Dr. Siddhartha Mukherjee DPHIL, M.D., Ph.D.Scientific Co-Founder · b. 1971
  • Dr. Lewis clayton Cantley Ph.D.Scientific Co-Founder · b. 1949
  • Dr. Scott W. Lowe Ph.D.Scientific Co-Founder
  • Dr. Gregory J. Hannon Ph.D.Scientific Co-Founder
  • Mr. Oliver Maddocks Ph.D.Co-Founder & Chief Scientific Officer
  • Dr. Benjamin Hopkins Ph.D.Scientific Co-Founder
  • Dr. Simon Knott Ph.D.Scientific Co-Founder

Financials

Income Statement

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue----0000
Cost of Revenue44.00K73.00K209.00K685.00K1.81M571.00K551.00K-
Gross Profit-44.00K-73.00K-209.00K-685.00K-1.81M-571.00K-551.00K-
Operating Expense12.70M12.36M19.24M36.80M47.31M36.49M31.11M-
Operating Income-12.74M-12.44M-19.45M-37.48M-49.12M-37.06M-31.66M-22.29M
EBITDA-12.70M-14.41M-18.20M-35.44M-46.56M-33.39M-29.52M-20.91M
Net Income-13.04M-16.74M-20.10M-36.79M-48.59M-34.10M-30.16M-21.09M
R&D8.23M8.35M11.92M21.66M29.58M18.30M18.63M10.96M
Interest Expense327.00K2.26M1.69M670.00K219.00K144.00K90.00K32.00K

Balance Sheet

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets1.85M1.22M21.43M153.22M118.38M74.37M45.36M22.90M
Total Liabilities55.33M69.88M5.54M6.71M14.97M9.48M6.97M4.31M
Total Equity-53.48M-68.66M15.89M146.51M103.41M64.89M38.39M18.59M
Cash653.00K251.00K16.60M7.16M17.80M13.01M9.99M8.67M
Total Debt4.75M16.05M685.00K2.35M8.03M6.21M3.85M1.51M
Net Debt4.09M15.80M-15.91M-4.80M-9.76M-6.80M-6.15M-7.16M

Cash Flow

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-10.31M-8.57M-17.70M-30.26M-39.03M-32.02M-24.67M-20.45M
Investing Cash Flow-31.00K-53.00K-1.40M-143.12M49.95M38.41M22.44M19.77M
Financing Cash Flow750.00K8.22M35.45M163.94M-287.00K-11.17M-787.00K-645.00K
Capital Expenditure31.00K53.00K1.21M2.03M321.00K180.00K146.00K16.00K
Free Cash Flow-10.34M-8.62M-18.91M-32.28M-39.35M-32.20M-24.82M-20.47M
FCF to OCF100.30%100.62%106.81%106.70%100.82%100.56%100.59%100.08%

Earnings

Report DateMar 3, 2021May 12, 2021Aug 4, 2021Nov 9, 2021Mar 10, 2022May 10, 2022Aug 9, 2022Nov 8, 2022Mar 28, 2023May 9, 2023Aug 3, 2023Nov 7, 2023Feb 28, 2024May 9, 2024Aug 6, 2024Nov 14, 2024Mar 28, 2025May 6, 2025Aug 5, 2025Nov 14, 2025Mar 30, 2026May 15, 2026Aug 4, 2026Nov 13, 2026
EPS Estimate--6.50-5.81-4.90-6.80--7.60-7.00--7.12-6.91-6.78-6.13--5.49-6.38-5.80--5.00-4.11-4.81-0.62-1.10-0.66
EPS Actual-3.35-8.40-6.40-6.40-5.40-8.10-6.80-8.80-7.96-6.52-6.20-5.58-6.00-6.38-5.60-5.80-5.46-5.45-3.91-3.62-3.74-131.45-2.84-
Surprise--29.23%-10.15%-30.61%20.59%-10.53%-25.71%-8.43%10.28%17.70%2.12%--2.00%9.09%5.86%-21.80%11.92%22.25%-21101.61%-158.18%-
Timing-Pre-marketPre-marketPre-marketPre-market-After-hoursAfter-hours-After-hoursPre-marketPre-marketPre-market-Pre-marketPre-marketPre-market-Pre-marketPre-market-Pre-marketPre-market-

Key Statistics & Ratios

Market Cap750.66M
Enterprise Value630.45M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book4.72
EPS-55.92
Book Value6.70
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-36.64M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-195.26%
Return on Assets-20.79%
Shares Outstanding25.84M
Shares Float18.51M
Beta-0.28
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Ownership Breakdown

Institutions
78.84%
Insiders
1.78%
Retail / Other
19.38%

Top Institutional Holders

  • Vivo Capital, LLC
    722.02K2.79%
  • Logos Global Management LP
    722.02K2.79%
  • Caligan Partners LP
    629.47K2.44%
  • Trails Edge Capital Partners, LP
    515.34K1.99%
  • Octagon Capital Advisors LP
    361.01K1.40%
  • Cormorant Asset Management, LLC
    306.22K1.19%
  • StemPoint Capital LP
    265.75K1.03%
  • Patient Square Capital LP
    175.05K0.68%
  • Affinity Asset Advisors, LLC
    144.40K0.56%
  • Franklin Templeton Inc
    133.51K0.52%
  • Marshall Wace Asset Management Ltd
    65.73K0.25%
  • The Goldman Sachs Group Inc
    61.57K0.24%
  • HRT FINANCIAL LLC
    58.00K0.22%
  • Suvretta Capital Management, LLC
    34.55K0.13%
  • Bank of America Corp
    33.02K0.13%
  • Renaissance Technologies Corp
    32.04K0.12%
  • BOOTHBAY FUND MANAGEMENT, LLC
    26.12K0.10%

Top Fund Holders

  • Polar Capital Biotech S Inc
    986.89K3.82%
  • Franklin Biotechnology Discv A(acc)USD
    337.09K1.30%
  • Franklin Biotechnology Discovery A
    180.71K0.70%

Stock Splits

  • Jun 17, 20251:20